Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
Pharmaceutical Executive November 1, 2008 Patrick Clinton	Over There Is it the FDA's responsibility to be in charge of inspections at foreign pharmaceutical plants?
Chemistry World June 10, 2013 Phillip Broadwith	Sandoz manufacturing woes continue Sandoz, the generic drugs arm of Swiss firm Novartis, has had an official warning from the US Food and Drug Administration over failings at one of its manufacturing plants.
The Motley Fool May 30, 2007 Brian Orelli	MedImmune's FDA Roller Coaster The vaccine maker is having its share of ups and downs, courtesy of the FDA. Investors, take note.
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
The Motley Fool February 21, 2008 Brian Lawler	A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin.
Chemistry World March 22, 2012 Andrew Turley	GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria.
The Motley Fool August 25, 2009 Brian Orelli	How to Keep From Losing Your Shirt More side effects for weight-loss drugs -- maybe.
Chemistry World September 12, 2011 Andrew Turley	Ireland Still Attractive to Pharma Industry The drug industry is still keen to invest in Ireland.
The Motley Fool August 9, 2010 Brian Orelli	Dendreon's in Trouble Provided you call a slap on the wrist from the FDA "trouble."
Pharmaceutical Executive May 1, 2005 Jill Wechsler	Washington Report: The Pendulum Swings FDA cracks down on safety. Haven't we been here before? Perhaps in the end, the public will have a better understanding of the dangers associated with all pharmaceuticals and how virtually impossible it is to guarantee a risk-free medical treatment.
Food Processing September 2006 David Joy	Guard against intentional contamination The food industry is fortunate Congress and FDA have not developed more specific requirements for food security.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool June 12, 2007 Brian Lawler	Adolor Is Still Swinging The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
Chemistry World July 29, 2013 Hepeng Jia	China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies.
Pharmaceutical Executive November 1, 2011 Jill Wechsler	The Drug Shortages Struggle Clamor for critical therapies prompts probes of prices, production practices.
Chemistry World July 16, 2010 Matt Wilkinson	Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.
The Motley Fool April 5, 2011 Frank Vinluan	GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep.
Pharmaceutical Executive September 1, 2008	How Do You Solve a Problem Like Manufacturing? Outsourcing saves pharmaceutical companies money -- except when it doesn't. Here's how to decide what to do.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
The Motley Fool May 27, 2010 Brian Orelli	This Rabid Agency Could Permanently Damage Your Portfolio The FDA has gotten a little out of control. The wonkiness of the FDA's actions makes it hard for investors to figure out what the agency will do.
The Motley Fool August 12, 2010 Brian Orelli	Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later.
The Motley Fool June 18, 2009 Brian Orelli	Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies?
The Motley Fool February 25, 2004 Brian Gorman	Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
The Motley Fool October 5, 2011 Brian Orelli	1 Sure Sign of an FDA Approval Transcept Pharmaceuticals shoots up 34% after announcing that the FDA had classified its resubmission as a class 1 response.
Pharmaceutical Executive July 10, 2014 Ben Comer	FDA Spread Thinly Abroad Is FDA capable of sufficiently overseeing global drug imports?
Pharmaceutical Executive October 1, 2011 Jill Wechsler	Pharma's Unlikely Best Friend Sidney Wolfe has been a thorn in the side of pharma and the FDA for almost 40 years, but is also a widely respected and highly vocal critic of industry practices and products, and a visible influence on regulatory policies.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
Pharmaceutical Executive July 1, 2013 Jill Wechsler	Seeking Supply Chain Security FDA wants pharma leaders to do more to ensure drug quality at home and abroad.
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
Chemistry World June 21, 2010 Sarah Houlton	Recalling pharma Recent drug withdrawals and manufacturing failures have highlighted the importance of ensuring that the medicines patients take contain what it says on the label.
The Motley Fool April 15, 2011 Frank Vinluan	GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands."
The Motley Fool November 7, 2008 Brian Orelli	Thinning Out the Pipeline The FDA says no to diet drugs from Sanofi-Aventis and Pfizer.
Salon.com May 16, 2001 Janelle Brown	The poison pill The media, the government and the drug companies: They're all to blame for the fen-phen debacle, says "Dispensing With the Truth" author Alicia Mundy...
Chemistry World November 22, 2010 Akshat Rathi	Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax.
Food Processing November 2007 David Joy	Regulatory Issues: New rules on reporting contamination Manufacturers will not have the option of handing recalls quietly. Information may even appear on FDA's web site.
The Motley Fool January 16, 2008 Brian Orelli	Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know.
Pharmaceutical Executive January 1, 2009 Jill Wechsler	FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order?
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
BusinessWeek May 21, 2007 John Carey	How Safe Is The Food Supply? The hamstrung FDA may be unable to prevent a contamination crisis.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
Chemistry World March 8, 2011 Andy Extance	GSK will pay off UK graduate tuition fees Potential undergraduate chemistry students concerned about their prospects in the face of plant closures and increased tuition fees have been given some cheer by pharmaceutical giant GlaxoSmithKline.